Jolly EC, Clatworthy MR, Lawrence C, Nathan PD, Farrington K. Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis. NDT Plus. 2009;2(4):300-302.Jolly EC, Clatworthy MR, Lawrence C, Nathan PD, Farrington K. Anti-CTLA-4 (CD152) monoclonal antibody-induced ...
We present the first reported case, to our knowledge, of immune-mediated nephritis following the administration of Tremelimumab (CP-675, 206), an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody. High-dose steroid therapy led to a rapid improveme...
CD5 + B cells predominate early in ontogeny and have been associated with autoantibody production. In chronic lymphocytic leukemia (CLL), B lymphocytes ex... HWS Jr,G Dighiero - 《Immunology Today》 被引量: 690发表: 1994年 Effects of monoclonal antibody therapy in patients with chronic lymphoc...
A phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immuno-globulin M monoclonal antibody to CD15. Clin Cancer Res 1995;1:965–72. CAS PubMed Google Scholar Barker E, Mueller BM, Handgretinger R, et al. Effect of a chimeric anti-ganglioside GD2 ...
the region of the target site where a therapeutic effect is expected (Jones and Martino2016). Ranibizumab, used for the treatment of wet age-related macular degeneration, a disease of the eye, is the first monoclonal antibody approved for targeted localised therapy by the Federal Drug ...
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol 2013; 163: 478–486. 87 Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol ...
CD-20 depleting antibodies Rituximab is a monoclonal antibody that binds to the B-cell surface molecule CD20 causing B-cell depletion. B cell therapy in RA aimed to reduce the production of pathogenic autoantibodies. If the patients suffer from incomplete responses to one previous TNF inhibitor, ...
(CD147) [13]. After the initial binding event, host proteases, such as furin, transmembrane serine protease 2 (TMPRSS2) and cathepsin L, cleave the head of S protein, transforming it into a spring-like structure; this action allows the viral membrane to fuse with the host membrane and ...
Monoclonal antibodies can exert synergistic antitumour effects in combination with other immunomodulatory approaches such as chemotherapy, radiotherapy, targeted therapy agents, vaccines or other immunomodulators. Advances in protein engineering have provided platforms for the development of novel antibody constru...
Combined CD137 (4–1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int. Immunol. 18, 325–333 (2006). Article CAS PubMed Google Scholar Melero, I. et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4–1BB ligand...